HEPA - a good buy opportunity? Very likely for me!
First of all, I am not an expert when it comes to pharmaceutical companies!
Why did I pick Hepion Pharmaceuticals (@hepionpharma)?
1. From a business perspective, they are healthy (Quick Ration of Assets vs. Liabilities is 9 to 1)
2. They came from a super high share price and are currently on a super low level
3. They are working on a product CRV431 (recently completed Phase 1 of 3) to tackle chronic liver disease and so far the results seem promising: Half a billion people worldwide are at risk unless new therapies are found.
CRV431 is Hepion’s clinical phase, lead oral drug candidate for nonalcoholic steatohepatitis (NASH) and viral hepatitis-induced liver disease. CRV431 meets all of Hepion’s criteria for an effective and unique pleiotropic liver disease drug.
Currently Phase 1 consists of three parts and the collective data from the Parts 1 and 2 demonstrate a favorable pharmacological, pharmacokinetic, and safety profile for CRV431. Part 3 data results are expected and with Phase 2 we might see bigger interest.
Take a look at the chart and the health of the company with future prospective - then shape your own opinion.
- This is no financial advice, so trade with care!-
For transparency reasons: I am invested in
HEPA with 2/10 of my stock account size.
Why did I pick Hepion Pharmaceuticals (@hepionpharma)?
1. From a business perspective, they are healthy (Quick Ration of Assets vs. Liabilities is 9 to 1)
2. They came from a super high share price and are currently on a super low level
3. They are working on a product CRV431 (recently completed Phase 1 of 3) to tackle chronic liver disease and so far the results seem promising: Half a billion people worldwide are at risk unless new therapies are found.
CRV431 is Hepion’s clinical phase, lead oral drug candidate for nonalcoholic steatohepatitis (NASH) and viral hepatitis-induced liver disease. CRV431 meets all of Hepion’s criteria for an effective and unique pleiotropic liver disease drug.
Currently Phase 1 consists of three parts and the collective data from the Parts 1 and 2 demonstrate a favorable pharmacological, pharmacokinetic, and safety profile for CRV431. Part 3 data results are expected and with Phase 2 we might see bigger interest.
Take a look at the chart and the health of the company with future prospective - then shape your own opinion.
- This is no financial advice, so trade with care!-
For transparency reasons: I am invested in
HEPA with 2/10 of my stock account size.
免責事項
これらの情報および投稿は、TradingViewが提供または保証する金融、投資、取引、またはその他の種類のアドバイスや推奨を意図したものではなく、またそのようなものでもありません。詳しくは利用規約をご覧ください。